The Pharma Letter12h
DMD market set for strong growth in coming years
The Duchenne muscular dystrophy (DMD) market is projected to grow from $2.3 billion in 2023 to $5.2 billion in 2033 across ...
State of Alaska Department of Revenue Sells 145 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...
Managed Healthcare Executive2d
Sarepta Announces Positive Results for Elevidys, Gene Therapy for Duchenne
Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...
The Pharma Letter3d
Legacy Pharma buys Roche’s InterMune unit
Caymen Islands-headquartered specialty drug firm Legacy Pharma has announced the completion of the acquisition of InterMune, ...
Deutsche Bank sets Sarepta stock target at $136, cites risks
Deutsche Bank (ETR:DBKGn) initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT), assigning a Hold rating to the ...
Sarepta initiated with a Hold at Deutsche Bank
Deutsche Bank analyst David Hoang initiated coverage of Sarepta (SRPT) with a Hold rating and $136 price target Maximize Your Portfolio with ...
Managed Healthcare Executive4d
Cumberland Pharmaceuticals Reports Promising Results Itetroban for DMD Patients
The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...
2 Growth Stocks to Buy Hand Over Fist in February
Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...
Why Sarepta Therapeutics, Inc. (SRPT) Is Among the Best Healthcare Stocks To Buy According to Analysts
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands ...